SymBio Pharmaceuticals (4582) Earnings: Revenue Decreases -27.3% YoY, Operating Loss Reported at 3.635 Billion Yen

SymBio Pharmaceuticals (4582) has released its financial results, reporting a revenue of 469 million yen, which represents a -27.3% decrease compared to the same period of the previous year. On the profit side, the company posted an operating loss of 3.635 billion yen, an ordinary loss of 3.608 billion yen, and a net loss attributable to owners of the parent of 3.619 billion yen, resulting in a basic earnings per share (EPS) of -50.89 yen. From a financial and valuation perspective, while cash and cash equivalents stand at 0.98 billion yen, operating cash flow and free cash flow remain negative at -4.58 billion yen and -4.65 billion yen, respectively. Furthermore, the Return on Equity (ROE) is -198.80% and the Return on Assets (ROA) is -108.11%, highlighting that profitability improvement remains a key focus moving forward.